Ocular Toxicity of Targeted Therapies

Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors.

(2017) M. Zweifel et al.   JOURNAL OF CLINICAL ONCOLOGY

AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.

(2017) T. A. Samuel et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.

(2017) J. Delord et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

(2017) J. R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.

(2017) S. O. Dolly et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.

(2017) S. Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies.

(2017) N. Houede et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies

(2012) T. Eisen et al.   JNCI-Journal of the National Cancer Institute

The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology

(2012) Michael W. Stewart   MAYO CLINIC PROCEEDINGS

Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

(2011) C. Lieu et al.   CLINICAL CANCER RESEARCH

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

(2011) Nizar M. Tannir et al.   EUROPEAN JOURNAL OF CANCER

Neurosensory retinal detachment due to sunitinib treatment

(2011) A Wegner et al.   EYE

Trichomegaly and Poliosis of the Eyelashes During Cetuximab Treatment of Metastatic Colorectal Cancer

(2011) Nelson A. Rodriguez et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Crizotinib in Anaplastic Large-Cell Lymphoma

(2011) Carlo Gambacorti-Passerini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

(2011) Helen A. Mintz-Hittner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-Induced Graves Disease From CTLA-4 Receptor Suppression

(2011) Gary Borodic et al.   OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY

Acute intraocular inflammation following intravitreal injection of bevacizumab - a large cluster of cases

(2010) Michael Fielden et al.   ACTA OPHTHALMOLOGICA

Cetuximab-Associated Elongation of the Eyelashes

(2010) Philip R. Cohen et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

(2010) U. Banerji et al.   CLINICAL CANCER RESEARCH

Central serous chorioretinopathy: an update on pathogenesis and treatment

(2010) M Gemenetzi et al.   EYE

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

AIDS-Related Kaposi's Sarcoma of the Gastrointestinal Tract

(2010) Steven Attia et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

(2010) Christophe Frémin et al.   Journal of Hematology & Oncology

Cetuximab-induced hypertrichosis of the scalp and eyelashes

(2010) Sergio Vano-Galvan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

(2010) E Jabbour et al.   LEUKEMIA

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retinal and Ocular Toxicity in Ocular Application of Drugs and Chemicals – Part II: Retinal Toxicity of Current and New Drugs

(2010) Fernando Marcondes Penha et al.   OPHTHALMIC RESEARCH

A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study)

(2010) Michel Michaelides et al.   OPHTHALMOLOGY

Trichomegaly of the Eyelashes After Colorectal Cancer Treatment With the Epidermal Growth Factor Receptor Inhibitor Cetuximab

(2009) Richard Bambury et al.   Clinical Colorectal Cancer

Persistent Corneal Epithelial Defect Associated With Erlotinib Treatment

(2009) Keegan S Johnson et al.   CORNEA

Erlotinib-induced trichomegaly in a male patient with pancreatic cancer

(2009) Muhammad Wasif Saif et al.   Cutaneous and Ocular Toxicology

Ocular Side Effects Associated with Imatinib Mesylate and Perifosine for Gastrointestinal Stromal Tumor

(2009) S. Serdar Dogan et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva®)

(2009) Gemma Márquez et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors

(2009) A. Craig Lockhart et al.   JOURNAL OF CLINICAL ONCOLOGY

PD0325901, a Mitogen-Activated Protein Kinase Kinase Inhibitor, Produces Ocular Toxicity in a Rabbit Animal Model of Retinal Vein Occlusion

(2009) Wenhu Huang et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Anterior Uveitis Complicating Zoledronic Acid Infusion

(2009) Annalisa Colucci et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)

(2008) M Georgopoulos et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Trichomegaly of the eyelashes following treatment with cetuximab

(2008) M. Vaccaro et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens

(2008) R. M. Giusti et al.   CLINICAL CANCER RESEARCH

Association of the CTLA-4 gene with Vogt–Koyanagi–Harada syndrome

(2008) Liping Du et al.   CLINICAL IMMUNOLOGY

Persisting Corneal Erosion Under Cetuximab (Erbitux) Treatment (Epidermal Growth Factor Receptor Antibody)

(2008) Claudia G Foerster et al.   CORNEA

Trichomegaly of the Eyelashes After Lung Cancer Treatment with the Epidermal Growth Factor Receptor Inhibitor Erlotinib

(2008) Fadi Braiteh et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

(2008) Alex A. Adjei et al.   JOURNAL OF CLINICAL ONCOLOGY

Unilateral Anterior Uveitis Complicating Zoledronic Acid Therapy in Prostate Cancer

(2008) FRÉDÉRIC BANAL et al.   JOURNAL OF RHEUMATOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ulcerative Keratitis in Gastrointestinal Stromal Tumor Patients Treated with Perifosine

(2008) Debraj Shome et al.   OPHTHALMOLOGY

Posterior reversible encephalopathy syndrome during sunitinib therapy

(2008) R. Cumurciuc et al.   REVUE NEUROLOGIQUE